Sign in

Filings

Finds words inside filing documents. Searching Citius Pharmaceuticals, Inc.'s filings · 56 documents indexed.

26 documents · 51 matches

  1. CTXR Citius Pharmaceuticals, Inc. 10-Q 2025-05-14

    Item 1A. Risk Factors.

    going concern and do not include any adjustments that might result from uncertainty about our ability to continue as a going
    7 matches in this document
  2. CTXR Citius Pharmaceuticals, Inc. 10-K 2025-12-23

    Item 16. Form 10-K Summary.

    going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses and has a working
    7 matches in this document
  3. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-11-04

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with
    1 match in this document
  4. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-10-26

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with
    1 match in this document
  5. CTXR Citius Pharmaceuticals, Inc. 10-Q 2026-08-14

    Item 6. Exhibits 37

    report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;
    5 matches in this document
  6. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-08-14

    going concern; our ability to regain compliance with Nasdaq’s continued listing standards; our ability to successfully commercialize LYMPHIR and establish
    1 match in this document
  7. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-06-01

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with
    1 match in this document
  8. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-05-15

    going concern; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining
    1 match in this document
  9. CTXR Citius Pharmaceuticals, Inc. 10-Q 2026-05-15

    Item 6. Exhibits 37

    report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;
    4 matches in this document
  10. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-04-29

    going concern; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability
    1 match in this document
  11. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-04-24

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product
    1 match in this document
  12. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-04-24

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product
    1 match in this document
  13. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-03-31

    going concern; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; early-stage
    1 match in this document
  14. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-03-10

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product
    1 match in this document
  15. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-03-04

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product
    1 match in this document
  16. CTXR Citius Pharmaceuticals, Inc. 8-K 2026-02-13

    going concern; our ability to maintain Nasdaq’s continued listing standards; our reliance on third-party logistics providers, distributors, and specialty
    1 match in this document
  17. CTXR Citius Pharmaceuticals, Inc. 10-Q 2026-02-13

    Item 6. Exhibits 30

    report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern;
    4 matches in this document
  18. CTXR Citius Pharmaceuticals, Inc. 8-K 2025-12-23

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product
    1 match in this document
  19. CTXR Citius Pharmaceuticals, Inc. 8-K 2025-12-01

    going concern ; our ability to successfully commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third
    1 match in this document
  20. CTXR Citius Pharmaceuticals, Inc. 8-K 2025-12-01

    going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; physician and patient acceptance of LYMPHIR
    1 match in this document

Page 1 of 2 · 26 documents